Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385202 | 1.00 | — | — | |
| SCHEMBL7291462 | 1.00 | CA2 (0.38) | CA2 | |
| SCHEMBL4757226 | 0.85 | CYP3A4 (0.35) | CA2 | |
| SCHEMBL2385824 | 0.85 | ALDH1A1 (0.32) | — | |
| SCHEMBL7293531 | 0.85 | CYP3A4 (0.35) | CA2 | |
| SCHEMBL196965 | 0.83 | — | — | |
| SCHEMBL29256269 | 0.79 | CA2 (0.38) | CA2 | |
| SCHEMBL124704 | 0.79 | CA2 (0.38) | CA2 | |
| SCHEMBL2386318 | 0.79 | — | — | |
| SCHEMBL23647292 | 0.76 | CA2 (0.44) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181305-B2 | Exendin-4 peptide analogues | SANOFI (FR) | 2015-11-10 | — | — | US | claimed |
| US-20120071402-A1 | Protease Stabilized, Pegylated Insulin Analogues | NOVO NORDISK A/S (DK) | 2012-03-22 | — | — | US | claimed |
| US-9447163-B2 | Purification of insulin | NOVO NORDISK A/S (DK) | 2016-09-20 | — | — | US | disclosed |
| US-20150038435-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | disclosed |
| EP-2820150-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | Novo Nordisk A/S (DK) | 2015-01-07 | — | — | EP | disclosed |
| US-20140073759-A1 | Purification of Insulin | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| EP-2670773-A1 | PURIFICATION OF INSULIN | Novo Nordisk A/S (DK) | 2013-12-11 | — | — | EP | disclosed |
| WO-2013128003-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2013-09-06 | — | — | WO | disclosed |
| WO-2012104339-A1 | PURIFICATION OF INSULIN | NOVO NORDISK A/S (DK) | 2012-08-09 | — | — | WO | disclosed |
| US-20120071402-A1 | Protease Stabilized, Pegylated Insulin Analogues | NOVO NORDISK A/S (DK) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073759-A1 | Purification of Insulin | IAPP, IGFBP4, INSRR | CA2 601/4885 |
| US-20150038435-A1 | N-TERMINALLY MODIFIED OLIGOPEPTIDES AND USES THEREOF | NGLY1, PTMS, VIP | CA2 4386/4885 |
| US-20120071402-A1 | Protease Stabilized, Pegylated Insulin Analogues | IDE, IAPP, IGFBP4 | CA2 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.